← All postsTopic

regulatory

3 posts on this topic, sorted most recent first.

2 May 2026·8 min read·regulatory
After the FDA crackdown: the state of US compounded GLP-1 in May 2026
Five months after the FDA closed enforcement discretion on 503A and 503B compounded tirzepatide and semaglutide, the US compounded-GLP-1 landscape has consolidated, contracted, and fragmented. The April 30 scorecard recap captured the snapshot. This is what changed in the four weeks after.
23 Apr 2026·4 min read·regulatory
Research use only: the legal shield, not the barrier
The phrase on every grey-market peptide site. What it actually means, what it does not mean, and why reading it wrong costs people money.
23 Apr 2026·5 min read·regulatory
US peptide regulation in 2026: the HHS reclass and what it means
RFK and HHS moved most restricted peptides back to Category 1 in early 2026. Here is what that actually does, and what it does not.

Other topics

tirzepatide 47 glp-1 25 mounjaro 22 semaglutide 12 buyers-guide 11 bangkok 10 thailand 9 wegovy 9 expat-asia 8 reader-question 6 vendor-trust 6 foundayo 5